Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report 2026

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size has grown exponentially in recent years. It will grow from $13.29 billion in 2025 to $17.03 billion in 2026 at a compound annual growth rate (CAGR) of 28.1%. The growth in the historic period can be attributed to improved disease awareness among cardiologists, increased diagnosis of rare cardiomyopathies, availability of targeted pharmacological therapies, expansion of specialty cardiac care centers, progress in genetic screening technologies.

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size is expected to see exponential growth in the next few years. It will grow to $45.09 billion in 2030 at a compound annual growth rate (CAGR) of 27.6%. The growth in the forecast period can be attributed to expansion of precision medicine approaches, growing development of next-generation gene-silencing therapies, rising investments in rare disease drug pipelines, increasing patient access to advanced cardiac diagnostics, stronger focus on disease-modifying treatments. Major trends in the forecast period include increasing adoption of transthyretin stabilizer therapies, rising use of rnAI-based treatment approaches, growing focus on early diagnosis and disease monitoring, expansion of personalized treatment regimens, increased investment in rare cardiac disease research.

The rising prevalence of chronic diseases is expected to drive the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the coming years. Chronic diseases are long-lasting conditions that develop gradually and persist for a year or more, often requiring ongoing medical care. The increasing prevalence of chronic conditions is linked to factors such as aging populations, sedentary lifestyles, unhealthy diets, rising obesity rates, and exposure to environmental pollutants. Treatments for transthyretin amyloid cardiomyopathy help stabilize transthyretin, reduce amyloid accumulation, improve heart function, and relieve symptoms, thereby better managing associated chronic conditions. For example, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition in 2023. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Therefore, the rising prevalence of chronic diseases is supporting the growth of the ATTR-CM treatment market.

Key companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are focusing on developing innovative therapies, such as oral prescription medications that stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medications are drugs prescribed by healthcare providers and taken by mouth, typically in the form of tablets, capsules, or liquids. For example, in November 2024, BridgeBio Pharma Inc., a US-based biotechnology company, received FDA approval for Attruby (acoramidis) to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This therapy stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials demonstrated that it is well-tolerated and provides rapid benefits by targeting the underlying cause of the disease.

In March 2024, Bayer AG, a Germany-based pharmaceutical company, acquired exclusive European marketing rights for acoramidis from BridgeBio Pharma for up to $310 million. Through this acquisition, Bayer aims to utilize its established cardiovascular commercial infrastructure to introduce a new oral therapy for transthyretin amyloid cardiomyopathy (ATTR-CM) in the European market, thereby expanding its presence in rare cardiovascular disease treatments. BridgeBio Pharma, a US-based biopharmaceutical company, develops acoramidis as a highly potent, orally administered small-molecule transthyretin (TTR) stabilizer designed to treat ATTR-CM.

Major companies operating in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc.

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the transthyretin amyloid cardiomyopathy treatment market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing inputs, and specialized diagnostic reagents used in RNAi and stabilizer therapies. North America and Europe are most affected due to reliance on cross-border pharmaceutical supply chains, while Asia-Pacific faces cost pressures in clinical manufacturing and trial materials. These tariffs contribute to higher treatment costs and slower therapy rollout in some regions. However, they are also encouraging localized drug manufacturing, regional clinical development, and long-term strengthening of domestic rare-disease treatment ecosystems.

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market research report is one of a series of new reports that provides transthyretin amyloid cardiomyopathy (attr-cm) treatment market statistics, including transthyretin amyloid cardiomyopathy (attr-cm) treatment industry global market size, regional shares, competitors with a transthyretin amyloid cardiomyopathy (attr-cm) treatment market share, detailed transthyretin amyloid cardiomyopathy (attr-cm) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloid cardiomyopathy (attr-cm) treatment industry. This transthyretin amyloid cardiomyopathy (attr-cm) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and potentially fatal condition caused by the accumulation of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure.

The primary types of ATTR-CM treatment include transthyretin stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), RNA interference (RNAi) therapy, and other approaches. Transthyretin stabilizers are medications that prevent the misfolding of TTR proteins, reduce amyloid deposits, and slow disease progression in ATTR-CM. Clinical indications include wild-type ATTR amyloidosis and hereditary ATTR amyloidosis. These treatments are used by a range of end users, including hospitals, home care providers, specialty clinics, and others.

The transthyretin amyloid cardiomyopathy (ATTR-CM) market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical and drug therapies, patient monitoring and disease management, specialized treatment centers and hospital services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloid cardiomyopathy (ATTR-CM) market also includes sales of tafamidis, patisiran, vutrisiran, and acoramidis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.